Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Wednesday, December 10, as ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

Biotech and health care exchange-traded funds let you invest in dozens or even hundreds of companies working on groundbreaking treatments, therapies and vaccines. Many, or all, of the products ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

The SPDR S&P Biotech ETF has an expense ratio of 0.35%, which is typical for ETFs focused on biotech or medical advancements. It's up 25% year-to-date as of Nov. 14, and has delivered a 10.5% average ...